Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Medipal Holdings Invests in Belgium’s Cell Therapy Developer
March 22, 2019
- Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
- Daiichi Sankyo’s Edoxaban Demonstrates Efficacy, Safety in AF Patients Undergoing Catheter Ablation
March 20, 2019
- Ono Files Multiple Myeloma Treatment Kyprolis for Once-Weekly Administration Regimen
March 20, 2019
- Servier, Oncodesign Join Forces to Develop Parkinson’s Disease Treatments
March 20, 2019
- NapaJen, Astellas Form Oligonucleotide Research Collaboration
March 19, 2019
- Ono Ties Up with AI Startup twoXAR on Drug Discovery
March 19, 2019
- 9 Month Cost-Effectiveness Analysis Possible If Companies Are Well-Prepared: Crecon Official
March 19, 2019
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- Hitachi Chemical Aspires to World’s No. 1 Regenerative Medicine CMO by Securing Bases in US, Europe through M&As
March 19, 2019
- Entrectinib Filed in Japan for ROS1 Lung Cancer: Chugai
March 18, 2019
- Alfresa Seeks to Expand Foothold in China via Tie-Up with 2nd Largest Drug Wholesaler
March 18, 2019
- Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
- Synthetic Rubber Form of Rivastach/Exelon Patch Approved: Ono/Novartis
March 15, 2019
- Aricept Generics Earn Lewy Body Dementia Indications
March 14, 2019
- Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
- Urief Authorized Generics Now Available: Daiichi Sankyo Espha
March 13, 2019
- FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27
March 13, 2019
- Vadadustat Demonstrates Efficacy, Safety in 4 PIII Studies for Renal Anemia: Mitsubishi Tanabe
March 13, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…